Loading...

Antibe Therapeutics Inc.

ATE.TO•TSX
Healthcare
Medical - Devices
CA$0.29
CA$0.03(13.46%)

Antibe Therapeutics Inc. (ATE.TO) Company Profile & Overview

Explore Antibe Therapeutics Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Antibe Therapeutics Inc. (ATE.TO) Company Profile & Overview

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.

SectorHealthcare
IndustryMedical - Devices
CEODaniel Marcel Legault

Contact Information

https://www.antibethera.com
416 922 3460
15 Prince Arthur Avenue, Toronto, ON, M5R 1B2

Company Facts

11 Employees
IPO DateJun 18, 2013
CountryCA

Frequently Asked Questions

;